| Altered expression of the MYCN oncogene modulates MRP gene expression and response to cytotoxic drugs in neuroblastoma cells. | neuroblastoma, |
| Down-regulation of endothelial cell growth inhibitors by enhanced MYCN oncogene expression in human neuroblastoma cells. | neuroblastoma, |
| MYCN oncogene and angiogenesis: down-regulation of endothelial growth inhibitors in human neuroblastoma cells. Purification, structural, and functional characterization. | neuroblastoma, |
| N-myc oncogene overexpression down-regulates leukemia inhibitory factor in neuroblastoma. | neuroblastoma,leukemia, |
| ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas. | neuroblastoma, |
| Enhanced MYCN oncogene expression in human neuroblastoma cells is associated with altered FGF receptor expression and cellular growth response to basic FGF. | neuroblastoma, |
| Amplification of the MYCN oncogene and deletion of putative tumour suppressor gene in human neuroblastomas. | neuroblastoma, |
| Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma. | neuroblastoma, |
| Overexpression of N-Myc rapidly causes acute myeloid leukemia in mice. | leukemia, |
| Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas. | lymphoma, |
| cyclin E expression in 2 t(11;14)-negative mantle cell lymphomas characterized by a cryptic t(2;14)(p24;q32) and identification of MYCN as a new lymphoma oncogene associated with a blastoid mantle cell lymphoma | lymphoma, |
| Binomial mitotic segregation of MYCN-carrying double minutes in neuroblastoma illustrates the role of randomness in oncogene amplification. | neuroblastoma, |
| Enhanced expression of the cellular oncogene MYCN and progression of human neuroblastoma. | neuroblastoma, |
| [Increased expression of the MYCN oncogene in human neuroblastoma cells and possible, new therapeutic approaches]. | neuroblastoma, |
| MYCN-regulated microRNAs repress estrogen receptor-alpha (ESR1) expression and neuronal differentiation in human neuroblastoma. | neuroblastoma, |
| Neuroblastoma progression correlates with downregulation of the lymphangiogenesis inhibitor sVEGFR-2. | neuroblastoma, |
| Enhanced MYCN oncogene expression in human neuroblastoma cells results in increased susceptibility to growth inhibition by TNF alpha. | neuroblastoma, |
| Cyclin E1 is a common target of BMI1 and MYCN and a prognostic marker for neuroblastoma progression. | neuroblastoma, |
| Coexpression of activated ALK with MYCN provides prosurvival signals that block this apoptotic response and allow continued expansion and oncogenic transformation of hyperplastic neuroblasts, thus promoting progression to neuroblastoma. | neuroblastoma, |
| The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma. | neuroblastoma, |